Company profile
Mirum Pharmaceuticals, Inc.
NASDAQ: MIRM · Healthcare · Biotechnology
#206 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
64CFH 66DQ 56GM 69SS 68
v0.1 · 65/100 weight · provisional
↑ market scale, 3-yr revenue growth · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$569.6M
Rev growth YoY (TTM)
+50.2%
Net income (FY)
-$23.4M
Employees
372
as of 2026-08-06
Market cap
$6.5B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$521.3M$521.3M2025
Net income-$23.4M-$23.4M2025
Operating income-$22.1M-$22.1M2025
Total assets$842.8M$842.8M2025
Liabilities$528.1M$528.1M2025
Equity$314.7M$314.7M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
UNITED STATES77%
Non-US23%
The read
What is Mirum Pharmaceuticals, Inc.’s revenue?
Mirum Pharmaceuticals, Inc. booked $521.3M in FY2025 revenue, growing 55% year over year — faster than most Healthcare companies we track, at a -4.5% net margin.
Peers · Healthcare
Bioventus Inc.66BOrganogenesis Holdings Inc.65BAtriCure, Inc.84B+Veracyte, Inc.82B+Inotiv, Inc.63CADMA Biologics, Inc.85ANeighbors
San Mateo →Key facts
CEOChristopher Peetz
SectorHealthcare
IndustryBiotechnology
HeadquartersFoster City, CA
ExchangeNASDAQ: MIRM
Employees372
IPO date2019-07-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.